Eosinophil: A Nonnegligible Predictor in COVID-19 Re-Positive Patients.
COVID-19
SARS-CoV-2
clinical index
eosinophils
re-positive
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
04
2021
accepted:
08
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
26
8
2021
Statut:
epublish
Résumé
Although vaccine resources are being distributed worldwide, insufficient vaccine production remains a major obstacle to herd immunity. In such an environment, the cases of re-positive occurred frequently, and there is a big controversy regarding the cause of re-positive episodes and the infectivity of re-positive cases. In this case-control study, we tracked 39 patients diagnosed with COVID-19 from the Jiaodong Peninsula area of China, of which 7 patients tested re-positive. We compared the sex distribution, age, comorbidities, and clinical laboratory results between normal patients and re-positive patients, and analysed the correlation between the significantly different indicators and the re-positive. Re-positive patients displayed a lower level of serum creatinine (63.38 ± 4.94 U/L
Identifiants
pubmed: 34394084
doi: 10.3389/fimmu.2021.690653
pmc: PMC8358389
doi:
Substances chimiques
Biomarkers
0
Serum Albumin
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
690653Informations de copyright
Copyright © 2021 Li, Yin, Yang, Bi, Wang, Ma, Fu, Ji, Jiang and Yu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Lab Anal. 2021 Jan;35(1):e23620
pubmed: 33118666
Cells. 2021 May 05;10(5):
pubmed: 34062964
Oxid Med Cell Longev. 2012;2012:171383
pubmed: 23326623
Int J Infect Dis. 2020 Apr;93:297-299
pubmed: 32147538
JAMA. 2020 Sep 8;324(10):943-945
pubmed: 32789500
J Allergy Clin Immunol. 2020 Jul;146(1):1-7
pubmed: 32344056
Infect Genet Evol. 2020 Nov;85:104511
pubmed: 32858231
J Clin Med Res. 2020 Jul;12(7):448-453
pubmed: 32655740
J Microbiol Immunol Infect. 2021 Feb;54(1):61-68
pubmed: 33468435
Front Public Health. 2020 Jul 10;8:368
pubmed: 32754569
In Vivo. 2021 Jan-Feb;35(1):641-648
pubmed: 33402521
J Leukoc Biol. 2001 Nov;70(5):691-8
pubmed: 11698487
J Pediatr. 1992 Jan;120(1):28-32
pubmed: 1731020
Clin Infect Dis. 2020 Nov 5;71(8):1962-1968
pubmed: 32472676
Stroke. 2020 Sep;51(9):2674-2682
pubmed: 32755348
J Infect. 2020 Aug;81(2):e49-e52
pubmed: 32335176
J Clin Med. 2021 Jan 15;10(2):
pubmed: 33467585
Genomics. 2021 Jun 30;113(5):3039-3049
pubmed: 34214628
Crit Care. 2020 May 15;24(1):227
pubmed: 32414393
Int J Infect Dis. 2020 Jun;95:183-191
pubmed: 32173576
J Med Virol. 2020 Oct;92(10):1938-1947
pubmed: 32311109
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Allergy. 2021 Feb;76(2):471-482
pubmed: 32562554
J Cell Mol Med. 2021 Jul;25(14):7052-7065
pubmed: 34137159
J Med Virol. 2021 Feb;93(2):1105-1110
pubmed: 32915476
Nature. 2020 Aug;584(7819):22-25
pubmed: 32760050
Front Med (Lausanne). 2020 Nov 04;7:585222
pubmed: 33251234
Am J Infect Control. 2020 Jun;48(6):725-726
pubmed: 32317126
JAMA. 2020 Apr 21;323(15):1502-1503
pubmed: 32105304
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
Cell Stem Cell. 2020 Dec 3;27(6):876-889.e12
pubmed: 33232663
Am J Respir Crit Care Med. 1999 Jun;159(6):1918-24
pubmed: 10351940
Ann Transl Med. 2020 Sep;8(17):1084
pubmed: 33145303